Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -111.55% is 97% above its 5-year average of -3686.83%, near the high end of its 5-year range (-37713.31%–0.92%).
23.49% below its 12-month average of -90.33%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -41.49%.
EBITDA MARGIN
-111.55%
EBITDA MARGIN AVG TTM
-90.33%
EBITDA MARGIN AVG 3Y
-3233.79%
EBITDA MARGIN AVG 5Y
-3686.83%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-23.49%
CURRENT VS 3Y AVG
+96.55%
CURRENT VS 5Y AVG
+96.97%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
BridgeBio Pharma, Inc.
Market Cap
$12.95B
EBITDA Margin
-111.55%
TTM Avg
-90.33%
3Y Avg
-3233.79%
5Y Avg
-3686.83%
Market Cap
$12.89B
EBITDA Margin
16.91%
TTM Avg
18.03%
3Y Avg
18.32%
5Y Avg
17.35%
Market Cap
$13.19B
EBITDA Margin
6.13%
TTM Avg
13.31%
3Y Avg
19.35%
5Y Avg
24.86%
Market Cap
$12.52B
EBITDA Margin
5.99%
TTM Avg
7.75%
3Y Avg
3.55%
5Y Avg
8.89%
Market Cap
$12.17B
EBITDA Margin
3.56%
TTM Avg
3.60%
3Y Avg
4.06%
5Y Avg
4.82%
Market Cap
$12.00B
EBITDA Margin
23.27%
TTM Avg
22.46%
3Y Avg
26.66%
5Y Avg
22.37%
Market Cap
$14.16B
EBITDA Margin
-16.47%
TTM Avg
-44.13%
3Y Avg
-328.90%
5Y Avg
-1924.25%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | $12.95B | -111.55% | -90.33% | -3233.79% | -3686.83% |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 16.91% | 18.03% | 18.32% | 17.35% |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 6.13% | 13.31% | 19.35% | 24.86% |
| Baxter International Inc. (BAX)vs › | $12.52B | 5.99% | 7.75% | 3.55% | 8.89% |
| Penumbra, Inc. (PEN)vs › | $12.49B | 14.73% | 11.96% | 9.26% | 5.60% |
| BrightSpring Health Services, Inc. Common Stock (BTSG)vs › | $12.17B | 3.56% | 3.60% | 4.06% | 4.82% |
| Encompass Health Corporation (EHC)vs › | $12.00B | 23.27% | 22.46% | 26.66% | 22.37% |
| Ascendis Pharma A/S (ASND)vs › | $14.16B | -16.47% | -44.13% | -328.90% | -1924.25% |
| DaVita Inc. (DVA)vs › | $11.47B | 19.98% | 20.97% | 19.78% | 20.10% |
| Bio-Techne Corporation (TECH)vs › | $11.36B | 28.74% | 23.07% | 27.33% | 30.04% |
Gross Margin
93.3%
EBITDA Margin
-111.5%
Operating Margin
-113.3%
Net Margin
-97.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -41.49% |
| 2026-03-31 | -53.86% |
| 2025-12-31 | -116.90% |
| 2025-09-30 | -119.14% |
| 2025-06-30 | -120.26% |
| 2025-03-31 | -88.39% |
| 2024-12-31 | -3819.45% |
| 2024-09-30 | -6962.37% |
| 2024-06-30 | -8024.22% |
| 2024-03-31 | 0.92% |
| 2023-12-31 | -10076.28% |
| 2023-09-30 | -3814.54% |
| 2023-06-30 | -8803.29% |
| 2023-03-31 | -6819.82% |
| 2022-12-31 | -6822.03% |
| 2022-09-30 | -37713.31% |
| 2022-06-30 | -106.57% |
| 2022-03-31 | -10141.32% |
| 2021-12-31 | -1273.38% |
| 2021-09-30 | -6366.64% |
| 2021-06-30 | -167.57% |
| 2021-03-31 | -36133.77% |
| 2020-12-31 | -104142.62% |
| 2020-09-30 | -1471.62% |
| 2019-12-31 | -566.35% |
| 2019-09-30 | -202.53% |
